Bottom line
RYHCX vs QAAGZX: the short answer
RYHCX (Health Care Fund) and QAAGZX (T. Rowe Price Health Sciences Portfolio) are both mutual funds.
But QAAGZX is far broader, holding 277 positions to 135 for RYHCX, so beyond the top names it adds exposure RYHCX doesn't have.
QAAGZX is cheaper at 0.86% vs 2.4% — a difference of $154 a year per $10,000 invested.
Over five years, QAAGZX returned +4.1% a year vs +4.1% for RYHCX.
Updated Nov 19, 2026
RYHCX vs QAAGZX side by side
| RYHCX | QAAGZX | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | Guggenheim | T. Rowe Price |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 2.4% | 0.86% |
| Annual cost per $10k | $240 | $86 |
| 10-yr cost on $10k (prospectus) | $2,782 | $1,061 |
| Max front load | 0% | None |
| 12b-1 fee | 1% | 0% |
| 1-yr return | +12.3% | +18.1% |
| 5-yr return (annualized) | +4.1% | +4.1% |
| 10-yr return (annualized) | +6.8% | +9.0% |
| Best quarter | +18.4% | +23.4% |
| Worst quarter | −14.6% | −15.8% |
| Net assets (fund) | $19.4M | $751.7M |
| Number of holdings | 135 | 277 |
| Portfolio turnover | 244% | 65% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | RYHCX | QAAGZX | Difference |
|---|---|---|---|
| 2025 | +13.3% | +18.1% | −4.8% |
| 2024 | −0.4% | +1.7% | −2.1% |
| 2023 | +4.8% | +3.0% | +1.9% |
| 2022 | −12.5% | −12.5% | 0.0% |
| 2021 | +18.1% | +13.1% | +5.0% |
| 2020 | +17.7% | +29.6% | −11.9% |
| 2019 | +21.6% | +29.0% | −7.3% |
| 2018 | +0.5% | +1.1% | −0.6% |
| 2017 | +22.3% | +27.6% | −5.3% |
| 2016 | −10.3% | −10.5% | +0.2% |
Source: Fund prospectus bar charts
Holdings overlap
17 of RYHCX's top 25 holdings also appear in QAAGZX's top 25.
| Holding | RYHCX | QAAGZX |
|---|---|---|
| Eli Lilly & Company | 3.63% | 14.06% |
| Johnson & Johnson | 2.88% | 6.64% |
| Abbvie Inc | 2.52% | 5.12% |
| Unitedhealth Group Inc | 2.22% | 5.88% |
| Merck & Company Inc | 2.04% | 4.00% |
| Thermo Fisher Scientific Inc | 1.61% | 2.53% |
| Amgen Inc | 1.56% | 1.80% |
| Abbott Laboratories | 1.42% | 1.91% |
| Gilead Sciences Inc | 1.39% | 2.79% |
| Vertex Pharmaceuticals Inc | 1.34% | 2.26% |
| Cvs Health Corp | 1.31% | 0.93% |
| Intuitive Surgical Inc | 1.31% | 1.89% |
| Danaher Corp | 1.30% | 1.44% |
| Bristol-myers Squibb Company | 1.22% | 2.12% |
| Stryker Corp | 1.21% | 1.78% |
Source: SEC Form N-PORT
RYHCX top 10
- Eli Lilly & Company — 3.63%
- Johnson & Johnson — 2.88%
- Abbvie Inc — 2.52%
- Unitedhealth Group Inc — 2.22%
- Merck & Company Inc — 2.04%
- Thermo Fisher Scientific Inc — 1.61%
- Amgen Inc — 1.56%
- Abbott Laboratories — 1.42%
- Gilead Sciences Inc — 1.39%
- Vertex Pharmaceuticals Inc — 1.34%
QAAGZX top 10
- Eli Lilly & Co — 14.06%
- Johnson & Johnson — 6.64%
- Unitedhealth Group Inc — 5.88%
- Abbvie Inc — 5.12%
- Merck & Co. Inc. — 4.00%
- Gilead Sciences Inc — 2.79%
- Thermo Fisher Scientific Inc — 2.53%
- Vertex Pharmaceuticals Inc — 2.26%
- Bristol-myers Squibb Co — 2.12%
- Abbott Laboratories — 1.91%
FAQ
What is the difference between RYHCX and QAAGZX?
Which is cheaper, RYHCX or QAAGZX?
Should I own both RYHCX and QAAGZX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.